Skip to main content
SpringerLink
Log in

The HMG-CoA reductase inhibitors — new safety concerns?

  • Drug reactions and interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Davidson MH. Safety Profiles for the HMG-CoA Reductase Inhibitors. Treatment and Trust. Drugs 2001; 61(2): 197–206

    Article  PubMed  CAS  Google Scholar 

  2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia: West of Scotland Prevention Study Group. N Engl J Med 1995; 333(20): 1301–7

    Article  PubMed  CAS  Google Scholar 

  3. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615–22

    Article  PubMed  CAS  Google Scholar 

  4. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9

    Google Scholar 

  5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: the Cholesterol and Recurrent Events Trial (CARE) investigators. N Engl J Med 1996; 335(14): 1001–9

    Article  PubMed  CAS  Google Scholar 

  6. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339(19): 1349–57

    Article  Google Scholar 

  7. Farmer JA, Torre-Amione G. Comparative Tolerability of the HMG-CoA Reductase Inhibitors. Drug Saf 2000 Sep; 23(3): 197–213

    Article  PubMed  CAS  Google Scholar 

  8. Ucar M, Mjörndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000 Jun; 22(6); 441–57

    Article  PubMed  CAS  Google Scholar 

  9. ECS Comment Archive. European Society of Cardiology: 20 August 2001. Bayer withdraws Baycol/Lipobay (cerivastatin) [online]. Available from URL: http://www.escardio.org/

  10. US Food and Drug Administration. Bayer voluntarily withdraws Baycol®. Media Release, 8 Aug 2001 [online]. Available from URL: http://www.fda.gov

  11. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 1994; 74, 667–73

    Article  PubMed  CAS  Google Scholar 

  12. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary Atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278–86

    Article  PubMed  CAS  Google Scholar 

  13. Pitt B. Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease: Atorvastatin versus Revascularization Treatment (AVERT) Investigators. N Engl J Med 1999; 341(2): 70–6

    Article  PubMed  CAS  Google Scholar 

  14. Pedersen TR, Wilhelmsen L, Faergeman O. Extended follow-up of patients in the Scandinavian Simvastatin Survival Study (4S) shows increased survival benefit of simvastatin therapy [abstract]. Circulation 1998; 98 Suppl.: 451

    Google Scholar 

  15. Jones P, Kafoneck S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolaemia (the CURVES study). Am J Cardiol 1998; 81(5): 582–7

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The HMG-CoA reductase inhibitors — new safety concerns?. Drugs Ther. Perspect 17, 11–15 (2001). https://doi.org/10.2165/00042310-200117240-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117240-00003

Keywords

Search

Navigation